Citadel Advisors
EVH icon

Citadel Advisors’s Evolent Health EVH Stock Holding History

Citadel Advisors’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.61M Sell
705,222
-1,149,795
-62% -$3.65M ﹤0.01% 6570
2025
Q4 		$7.42M Sell
1,855,017
-441,795
-19% -$2.46M ﹤0.01% 3674
2025
Q3 		$19.4M Buy
2,296,812
+1,709,889
+291% +$16.6M ﹤0.01% 2381
2025
Q2 		$6.61M Buy
586,923
+455,275
+346% +$4.18M ﹤0.01% 3651
2025
Q1 		$1.25M Sell
131,648
-350,372
-73% -$3.54M ﹤0.01% 6473
2024
Q4 		$5.42M Buy
482,020
+283,549
+143% +$4.98M ﹤0.01% 3830
2024
Q3 		$5.61M Sell
198,471
-645,047
-76% -$16.6M ﹤0.01% 3761
2024
Q2 		$16.1M Buy
843,518
+689,473
+448% +$17.6M ﹤0.01% 2223
2024
Q1 		$5.05M Sell
154,045
-641,704
-81% -$20.5M ﹤0.01% 3942
2023
Q4 		$26.3M Sell
795,749
-884,315
-53% -$25M 0.01% 1750
2023
Q3 		$45.7M Buy
1,680,064
+486,145
+41% +$13.5M 0.01% 1137
2023
Q2 		$36.2M Sell
1,193,919
-241,561
-17% -$7.81M 0.01% 1315
2023
Q1 		$46.6M Sell
1,435,480
-1,163,341
-45% -$36.8M 0.01% 1136
2022
Q4 		$73M Buy
2,598,821
+920,972
+55% +$26.4M 0.02% 838
2022
Q3 		$60.3M Sell
1,677,849
-16,659
-1% -$587K 0.01% 918
2022
Q2 		$52M Buy
1,694,508
+633,966
+60% +$18.5M 0.01% 990
2022
Q1 		$34.3M Buy
1,060,542
+778,289
+276% +$20.4M 0.01% 1419
2021
Q4 		$7.81M Buy
282,253
+230,135
+442% +$6.6M ﹤0.01% 3497
2021
Q3 		$1.62M Sell
52,118
-278,848
-84% -$6.69M ﹤0.01% 6897
2021
Q2 		$6.99M Buy
330,966
+74,299
+29% +$1.49M ﹤0.01% 3738
2021
Q1 		$5.18M Buy
256,667
+76,070
+42% +$1.45M ﹤0.01% 4175
2020
Q4 		$2.9M Sell
180,597
-194,110
-52% -$2.57M ﹤0.01% 4641
2020
Q3 		$4.65M Buy
374,707
+211,694
+130% +$2.49M ﹤0.01% 3274
2020
Q2 		$1.16M Buy
163,013
+644
+0.4% +$4.31K ﹤0.01% 5554
2020
Q1 		$882K Sell
162,369
-212,212
-57% -$1.9M ﹤0.01% 5555
2019
Q4 		$3.39M Buy
374,581
+312,219
+501% +$2.54M ﹤0.01% 3618
2019
Q3 		$448K Buy
+62,362
New +$448K ﹤0.01% 6935
2019
Q2 		– Sell
-22,978
Closed -$272K – 9342
2019
Q1 		$289K Buy
+22,978
New +$364K ﹤0.01% 7667
2018
Q3 		– Sell
-36,454
Closed -$870K – 9329
2018
Q2 		$767K Sell
36,454
-115,458
-76% -$2.19M ﹤0.01% 5664
2018
Q1 		$2.17M Sell
151,912
-1,023,868
-87% -$14.7M ﹤0.01% 3622
2017
Q4 		$14.5M Buy
1,175,780
+480,036
+69% +$6.77M 0.01% 1395
2017
Q3 		$12.4M Buy
695,744
+392,531
+129% +$8.09M 0.01% 1423
2017
Q2 		$7.69M Sell
303,213
-50,026
-14% -$1.2M 0.01% 1687
2017
Q1 		$7.88M Buy
353,239
+207,499
+142% +$3.98M 0.01% 1617
2016
Q4 		$2.16M Sell
145,740
-111,782
-43% -$2.2M ﹤0.01% 2859
2016
Q3 		$6.34M Buy
+257,522
New +$6.02M 0.01% 1745
2016
Q2 		– Sell
-15,676
Closed -$166K – 6955
2016
Q1 		$166K Sell
15,676
-132,938
-89% -$1.37M ﹤0.01% 5767
2015
Q4 		$1.8M Buy
148,614
+30,746
+26% +$453K ﹤0.01% 2846
2015
Q3 		$1.88M Sell
117,868
-24,491
-17% -$478K ﹤0.01% 3020
2015
Q2 		$2.78M Buy
+142,359
New +$2.65M ﹤0.01% 2677

Other funds holding EVH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RF
Rubicon Founders Nashville, Tennessee $138M AUM 61.96% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's EVH Position: Q1 2026 in Review

Citadel Advisors reduced its Evolent Health (EVH) stake by 62% in Q1 2026, selling an estimated $3.65M and leaving 705,222 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #6570.

Citadel Advisors first reported a position in EVH in Q2 2015 and has held it in 40 quarters since. The position peaked at $73M in Q4 2022. 191 funds tracked by Wall St. Rank hold EVH as of Q1 2026.

  • Citadel Advisors held 705,222 shares of Evolent Health worth $1.61M as of Q1 2026.
  • Citadel Advisors sold 1,149,795 Evolent Health shares in Q1 2026, an estimated $3.65M.
  • Evolent Health made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6570 holding.
  • Citadel Advisors first reported a position in Evolent Health in Q2 2015 and has held it in 40 quarters since.
  • Citadel Advisors's Evolent Health position peaked at $73M in Q4 2022.
  • 191 funds tracked by Wall St. Rank held Evolent Health as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.